Orphazyme A/S EBIT

As of the most recent data (June 2026), ORPHY shows a EBIT of $-4.8M. That compares with $-36M in the prior-year period — up 86.8% year over year. That is below the Healthcare sector average of $110B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ORPHY's EBIT is now $-4.8M (was $-36M) — a 86.8% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Orphazyme A/S is outperforming or lagging.

The Healthcare sector average EBIT is about $110B. Orphazyme A/S is at $-4.8M, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how ORPHY stacks up against individual peers as well.

Tracking ORPHY's ebit over time shows whether Orphazyme A/S is scaling, shrinking, or reshaping that part of the business. The current reading is $-4.8M That compares with $-36M in the prior-year period — up 86.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Orphazyme A/S's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-4.8M) with ownership activity and broader fundamentals.